Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Targeted Anticancer Therapies Congress 2024

Surrogate endpoints in early phase drug development

Minimal residual disease as a surrogate for early drug development

Date

27 Feb 2024

Session

Surrogate endpoints in early phase drug development

Topics

Laboratory Diagnostics;  Translational Research;  Genetic and Genomic Testing

Tumour Site

Leukaemias;  Lymphomas

Presenters

Davide Rossi

Authors

D. Rossi

Author affiliations

  • Haematology, EOC - Amministrazione IOSI, 6500 - Bellinzona/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Panel discussion

Presenter: All Speakers

Session: Surrogate endpoints in early phase drug development

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.